Clinical Trial Search

Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale

Primary: Change in Stress — -5.0 units on a scale — p=<0.001

Primary: Number of Participants With Dose Limiting Toxicities (DLT) in Part 1 - Safety Analysis Set (SAS) — 0; 0; 0; 0 Participants

Primary: Postconcussive Sensory Symptoms — 19.9; 18.9; 2.9; 20.6 score on a scale

Primary: Time in Target Blood Glucose Range (BG 70-180mg/dL) — 60.5; 61.4 percentage of time within target range

Primary: Percentage of Participants With Improvement in DRSS by ≥ 2 Steps at 48 Weeks of Treatment in the Study Eye — 0.0; 1.9 percentage of participants

Primary: Number of Adults 50-64 Years Old With Polymerase-chain Reaction (PCR) Confirmed Influenza Tests — 559; 925 participants — p=<0.05

Primary: Part 1: Number of Participants With Adverse Events That Are Related to Treatment With ISIS 814907 — 3; 0; 5; 4 Participants

Primary: Sustained Virologic Response (SVR) by Intervention Group Stratified by Defined Risk for Treatment Failure (Minimal vs Elevated) — 638; 416; 233; 76 Participants

Primary: Binocular Visual Performance (LogMAR) — -0.10; -0.10; -0.07; -0.11 logMAR

Primary: Number of Participants Evaluated for Infection During Treatment Intervention — 10 Participants

Primary: Proportion of Discharges With Opioid Prescriptions Above Prescribing Guidelines — 0.254; 0.275; 0.368 Proportion of discharges

Primary: "Beck Depression Inventory" Scores — 17.75; 30.62; 13.58; 31.18 score on a scale

Primary: HIV Transcription (Cell-associated HIV RNA) in Peripheral Blood — 10.45; 57.38 copies/million cells

Primary: Time of First Cannula in Until Satisfactory Stent Placement and Cannula Out — 2.55; 3.06 minutes — p=0.45490734